Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been given an average rating of “Buy” by the twenty brokerages that are presently covering the stock. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $55.46.
Several equities research analysts recently commented on the company. WBB Securities reiterated a “strong-buy” rating and set a $60.00 target price (up from $40.00) on shares of Sarepta Therapeutics in a report on Tuesday, September 20th. Needham & Company LLC raised their target price on Sarepta Therapeutics from $47.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, September 20th. Wedbush reiterated an “outperform” rating and set a $66.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 20th. Cowen and Company upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $64.00 target price on the stock in a report on Tuesday, September 20th. Finally, Oppenheimer Holdings Inc. raised their target price on Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday, September 19th.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,217,600.00. Following the completion of the transaction, the chief executive officer now owns 89,983 shares in the company, valued at approximately $4,499,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas raised its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $211,000. First Allied Advisory Services Inc. raised its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Finally, National Planning Corp raised its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Institutional investors own 72.09% of the company’s stock.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 57.83 on Wednesday. The firm’s market capitalization is $2.77 billion. The company’s 50 day moving average price is $30.90 and its 200 day moving average price is $22.21. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $61.60.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the firm posted ($0.87) earnings per share. On average, analysts expect that Sarepta Therapeutics will post ($4.17) EPS for the current fiscal year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.